Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$7.77
-19.6%
$10.15
$3.60
$11.99
$107.43M0.4442,826 shs32,633 shs
LadRx Corp stock logo
CYTR
LadRx
$0.09
$0.05
$0.86
$4.14MN/A99,706 shs4,000 shs
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
$0.50
$0.22
$8.67
$450.52M1.25464,030 shs21,870 shs
BiomX Inc. stock logo
PHGE
BiomX
$0.45
-39.4%
$0.50
$0.34
$3.86
$12.54M1.43106,529 shs53,300 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$1.97
-0.8%
$3.19
$1.81
$26.96
$11.38M0.54133,066 shs380,089 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-0.83%+6.66%+20.00%+3.46%+53.25%
LadRx Corp stock logo
CYTR
LadRx
0.00%0.00%0.00%0.00%0.00%
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
BiomX Inc. stock logo
PHGE
BiomX
+2.05%-2.18%-10.93%-21.27%-87.05%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-0.76%-1.75%-50.38%-69.48%-88.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
4.3575 of 5 stars
3.53.00.04.40.62.51.3
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/AN/AN/AN/AN/AN/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.7226 of 5 stars
3.52.00.04.61.13.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
3.00
Buy$12.0054.44% Upside
LadRx Corp stock logo
CYTR
LadRx
0.00
N/AN/AN/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
0.00
N/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
3.00
Buy$21.004,587.50% Upside
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$72.333,581.09% Upside

Current Analyst Ratings Breakdown

Latest CYTR, XFOR, PHGE, CSBR, and IDRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
BiomX Inc. stock logo
PHGE
BiomX
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/2/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $7.00
4/4/2025
BiomX Inc. stock logo
PHGE
BiomX
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$50.15M2.14N/AN/A($0.14) per share-55.50
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/AN/AN/AN/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/A0.29$0.56 per shareN/A
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/A$0.70 per shareN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$2.56M4.44N/AN/A$3.90 per share0.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$7.28M-$0.0617.66N/A10.97%656.65%24.04%N/A
LadRx Corp stock logo
CYTR
LadRx
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/A
BiomX Inc. stock logo
PHGE
BiomX
-$28.32M-$0.85N/AN/AN/AN/A-127.82%-56.50%N/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$37.45M$2.140.92N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)

Latest CYTR, XFOR, PHGE, CSBR, and IDRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/AN/AN/AN/AN/A
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/AN/AN/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/AN/AN/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/A
0.99
0.99
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
N/A
1.56
1.56
BiomX Inc. stock logo
PHGE
BiomX
0.51
2.84
2.84
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.30
3.70
3.58

Institutional Ownership

CompanyInstitutional Ownership
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
41.30%
LadRx Corp stock logo
CYTR
LadRx
N/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
12.18%
BiomX Inc. stock logo
PHGE
BiomX
40.57%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%

Insider Ownership

CompanyInsider Ownership
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
46.98%
LadRx Corp stock logo
CYTR
LadRx
N/A
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
5.05%
BiomX Inc. stock logo
PHGE
BiomX
1.17%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
2.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
14313.83 million7.33 millionOptionable
LadRx Corp stock logo
CYTR
LadRx
N/A45.04 millionN/ANot Optionable
Idera Pharmaceuticals, Inc. stock logo
IDRA
Idera Pharmaceuticals
3262.36 million59.21 millionOptionable
BiomX Inc. stock logo
PHGE
BiomX
12026.18 million44.04 millionNot Optionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million5.65 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
X4 Pharmaceuticals Inc News (XFOR) - Investing.com
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Champions Oncology stock logo

Champions Oncology NASDAQ:CSBR

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

LadRx stock logo

LadRx NASDAQ:CYTR

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

Idera Pharmaceuticals stock logo

Idera Pharmaceuticals NASDAQ:IDRA

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

BiomX stock logo

BiomX NYSEMKT:PHGE

$0.45 -0.29 (-39.38%)
Closing price 07/3/2025 03:45 PM Eastern
Extended Trading
$0.44 -0.01 (-1.79%)
As of 07/3/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$1.96 -0.02 (-0.76%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$1.92 -0.05 (-2.29%)
As of 07/3/2025 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.